Charles M. Hall

General Partner at Apjohn Group LLC

Charles M. Hall

Charles M. Hall

General Partner at Apjohn Group LLC

Overview
RelSci Relationships

292

Number of Boards

1

Relationships
RelSci Relationships are individuals Charles M. Hall likely has professional access to. A relationship does not necessarily indicate a personal connection.

Director & General Partner at Apjohn Ventures Fund

Relationship likelihood: Strong

Fund Advisor at Hopen LS Manager II LLC

Relationship likelihood: Strong

Chairman & Chief Executive Officer at Rubicon Genomics, Inc.

Relationship likelihood: Strong

Founder at Apjohn Group LLC

Relationship likelihood: Strong

Founding Partner at Apjohn Group LLC

Relationship likelihood: Strong

General Partner at Apjohn Group LLC

Relationship likelihood: Strong

General Partner at Apjohn Group LLC

Relationship likelihood: Strong

President at Open Prairie Ventures, Inc.

Relationship likelihood: Strong

Co-Founder at Seneca Partners, Inc.

Relationship likelihood: Strong

Founding Partner at Apjohn Group LLC

Relationship likelihood: Strong

Paths to Charles M. Hall
Potential Connections via
Relationship Science
You
Charles M. Hall
General Partner at Apjohn Group LLC
Education
Career History
General Partner
Current

Apjohn Group LLC invests in pharamaceutical companies. It works with innovators to launch life science companies. The company is headquartered in Kalamazoo, MI.

Fellow
Current

University of Vienna is a public university located in Vienna, Austria. It was founded by Duke Rudolph IV in 1365

Vice President-Product Development
Prior

CNS, Inc. manufactures pharmaceutical products and health supplements. It markets the products as a treatment for allergies, snoring, and general nasal congestion. The company also sells FiberChoice, a chewable fiber supplement and a Breathe Right-branded throat rinse for snorers. It was founded in 1982 and is headquartered in Minneapolis, MN.

Boards & Committees
Director
Current

NephRx Corp. provides therapeutic products for the treatment of kidney failures. The firm's flagship product includes NX001 is a kidney growth factor peptide for acute renal failure that is currently in preclinical development for treatment of delayed graft function in transplant patients. The company was founded in 2001 by Pratik Shah and is headquartered in Kalamazoo, Michigan.

This web site is not endorsed by, directly affiliated with, maintained, authorized, or sponsored by Charles M. Hall. The use of any trade name or trademark is for identification and reference purposes only and does not imply any association with the trademark holder. The Presence of Charles M. Hall's profile does not indicate a business or promotional relationship of any kind between RelSci and Charles M. Hall.